Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Ítems similars

• Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
  per: Coates, LC, et al.
  Publicat: (2021)
• Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
  per: Iain B. McInnes, et al.
  Publicat: (2022-10-01)
• Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
  per: McGagh, D, et al.
  Publicat: (2020)
• Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
  per: Loredana Frasca, et al.
  Publicat: (2018-09-01)
• Treat-to-target in PsA: methods and necessity
  per: Dures, E, et al.
  Publicat: (2020)